Larimar Therapeutics(DE:ZA71)
€2.20+0.06 (+6.80%)
DE:ZA71
Larimar Therapeutics stock forecast
€2.20
At close:+0.06 (+6.80%)
Larimar Therapeutics (ZA71) Stock Forecast & Price Target
3 Followers
ZA71 Analyst Ratings
Strong Buy
4Buy0Hold0Sell
Based on 4 analysts giving stock ratings to Larimar Therapeutics in the past 3 months
ZA71 Stock 12 Month Forecast
Average Price Target
€14.26▲(548.03% Upside)Based on 4 Wall Street analysts offering 12 month price targets for Larimar Therapeutics in the last 3 months. The average price target is EUR 14.26 with a high forecast of EUR 22.28 and a low forecast of EUR 8.91. The average price target represents a 548.03% change from the last price of EUR 2.20.
Past 12 Months12 Month ForecastJan2026Oct2026
High€22.28
Average€14.26
Low€8.91
Highest Price TargetHighest€22.28Average Price Target€14.26Lowest Price TargetLowest€8.91
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Ram Selvaraju | H.C. Wainwright | €8.91 | buy | 305.02%Upside | Reiterated | 11/10/26 | ||
| Tessa Romero | J.P. Morgan | ― | buy | ― | Reiterated | 11/09/26 | ||
| Francois Brisebois | LifeSci Capital | €22.28 | buy | 912.55%Upside | Reiterated | 09/28/26 | ||
| Basma Radwan | Leerink Partners | €10.69→€11.58 | buy | 426.52%Upside | Reiterated | 09/14/26 | ||
| Myles Minter | William Blair | ― | buy | ― | Reiterated | 08/05/26 | ||
| Laura Chico | Wedbush | €10.69→€9.80 | buy | 345.52%Upside | Reiterated | 08/05/26 | ||
| Samantha Semenkow | Citi | €12.47 | buy | 467.03%Upside | Reiterated | 06/30/26 | ||
| Christopher Chen | Robert W. Baird | €6.24→€4.46 | buy | 102.51%Upside | Reiterated | 06/30/26 | ||
| Catherine Novack | JonesTrading | €6.24→€11.58 | buy | 426.52%Upside | Reiterated | 02/24/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Ram SelvarajuH.C. Wainwright | BuyReiterated€8.91 | 11/10/26 | 305.02%Upside | ||
| Tessa RomeroJ.P. Morgan | BuyReiterated | 11/09/26 | ― | ||
| Francois BriseboisLifeSci Capital | BuyReiterated€22.28 | 09/28/26 | 912.55%Upside | ||
| Basma RadwanLeerink Partners | BuyReiterated€10.69→€11.58 | 09/14/26 | 426.52%Upside | ||
| Myles MinterWilliam Blair | BuyReiterated | 08/05/26 | ― | ||
| Laura ChicoWedbush | BuyReiterated€10.69→€9.80 | 08/05/26 | 345.52%Upside | ||
| Samantha SemenkowCiti | BuyReiterated€12.47 | 06/30/26 | 467.03%Upside | ||
| Christopher ChenRobert W. Baird | BuyReiterated€6.24→€4.46 | 06/30/26 | 102.51%Upside | ||
| Catherine NovackJonesTrading | BuyReiterated€6.24→€11.58 | 02/24/26 | 426.52%Upside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Larimar Therapeutics
3 Months
Success Rate5/9 ratings generated profit
56%
Average Return
+8.53%
Copying Catherine Novack's trades and holding each position for 3 Months would result in 55.56% of your transactions generating a profit, with an average return of +8.53% per trade.
1 Year
Success Rate6/13 ratings generated profit
46%
Average Return
-1.26%
Copying Samantha Semenkow's trades and holding each position for 1 Year would result in 46.15% of your transactions generating a profit, with an average return of -1.26% per trade.
2 Years
Success Rate2/13 ratings generated profit
15%
Average Return
-34.65%
Copying Samantha Semenkow's trades and holding each position for 2 Years would result in 15.38% of your transactions generating a profit, with an average return of -34.65% per trade.
ZA71 Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 12 | 10 | 6 | 4 | 3 |
| Buy | 3 | 2 | 1 | 1 | 1 |
| Hold | 1 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 16 | 12 | 7 | 5 | 4 |
In the current month, ZA71 has received 4 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ZA71 average Analyst price target in the past 3 months is 14.26.
ZA71 Financial Forecast
Consensus€0.00
ZA71 Sales Forecast
Next quarter’s sales forecast for ZA71 is EUR 0 with a range of ― to ―. The previous quarter’s sales results were EUR 0. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
ZA71 Stock Forecast FAQ
What is DE:ZA71’s average 12-month price target, according to analysts?
Based on analyst ratings, Larimar Therapeutics’s 12-month average price target is €14.26.
What is DE:ZA71’s upside potential, based on the analysts’ average price target?
Larimar Therapeutics has 548.03% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Larimar Therapeutics a Buy, Sell or Hold?
Larimar Therapeutics has a consensus rating of Strong Buy, which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.
What is Larimar Therapeutics’s share price target?
The average share price target for Larimar Therapeutics is €14.26. This is based on 4 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €22.28, and the lowest forecast is €8.91. The average share price target represents a 548.03% increase from the current price of €2.2.
What do analysts say about Larimar Therapeutics?
Larimar Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Street analysts.
How can I buy shares of Larimar Therapeutics?
To buy shares of DE:ZA71, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
